Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes
Status:
Completed
Trial end date:
2000-12-01
Target enrollment:
Participant gender:
Summary
To determine, in subjects with Type 2 Diabetes Mellitus:
1. Whether glycemic control can be achieved at least as effectively with an insulin regimen
involving pre-meal EXUBERA™ (inhaled insulin) plus a single bedtime Ultralente injection
as with a conventional subcutaneous insulin regimen involving 2 mixed Regular/NPH
insulin injections per day.
2. The toleration and safety of EXUBERA™ (inhaled insulin) therapy and its effects after 6
months, if any, on measures of pulmonary function.